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ABSTRACT 
Background: Left ventricular assist devices (LVAD) are an approved treatment for 
end-stage heart failure (HF). Several devices have been developed over the years, 
including two new-generation ones (HeartMate 3 and HeartWare), but uncertainty 
persists on their comparative effectiveness. We conducted a network meta-analysis on 
randomized trials on LVAD for adults with HF. 
Methods and Results: Pertinent studies were searched in several databases. Selected 
outcomes were extracted, including death, stroke, and bleeding. Incident relative risks 
(RR) were computed with network meta-analysis, with 95% confidence intervals and 
P-scores (with highest values indicating the best therapy). Four trials were identified, 
one comparing HeartMate VE vs medical management, one HeartMate II vs 
HeartMate XVE, one HeartMate 3 vs HeartMate II, and one HeartWare vs HeartMate 
II, totaling 1069 patients followed for an average of 20 months. Using HeartMate 
XVE/VE as benchmark, continuous-flow LVADs provided significant better outcome 
for death, the RR for death was 0.71 (95% confidence interval=0.44-1.14; P-
score=0.914) for HeartMate 3, 0.98 (0.61-1.56; 0.404) for HeartWare, 0.80 (0.55-
1.17; 0.748) for HeartMate II, and 1.47 (1.19-1.82; 0.016) for medical management. 
Appraising other outcomes, continuous-flow devices proved better than first-
generation pulsatile-flow devices for bleeding, device failure, device thrombosis, 
drive-line exit-site infection, renal dysfunction, respiratory failure, stroke and sepsis.  
Conclusions: New-generation LVAD represent a paradigm shift in the management 
of end-stage HF. Further technological refinements and higher quality and larger trials 
are crucial to improve decision-making and clinical outcomes in this challenging 
clinical setting. 
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ABBREVIATIONS AND ACRONYMS 
HF  Heart failure 
INTERMACS Interagency Registry for Mechanically Assisted Circulatory Support 
LVAD  Left ventricular assist device 
PRISMA Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
P-score Probability of being the best treatment 
RCT  Randomized controlled trial 
RR  Relative risk 
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INTRODUCTION 
 Technologic improvements in mechanical circulatory support joined to the 
relative shortage of donor organs have stemmed the adoption of left ventricular assist 
devices (LVAD) for end-stage heart failure (HF) (1). These pumps have improved the 
quality of life and overall survival of patients when all other therapeutic options are 
exhausted. Moreover, LVAD have progressively evolved their indication, now termed 
“device strategy”, becoming a treatment to support end-stage HF patients in several 
different clinical scenarios: as a bridge to heart transplantation, as a destination 
therapy or more recently, as bridge to decision or even as recovery (2-4). 
 In addition to trends in device strategy, patients profile at the time of implant, 
defined by INTERMACS (Interagency Registry for Mechanically Assisted 
Circulatory Support), have evolved (5). Risk stratification of candidates for LVAD 
implantation has proved to be critical for appropriate LVAD candidate selection to 
help foster good patient outcomes and ensure appropriate resource utilization (6-8). 
Initially the implantable pulsatile pump, HeartMate VE demonstrated its benefits 
compared to medical management alone in end-stage heart failure patients (9). Then, 
with the advent of continuous-flow pumps, LVADs gained momentum and the 
HeartMate II has become widely adopted (10).  Yet, a larger use of LVADs was 
associated with an increased risk of pump thrombosis (11), in comparison with the 
low rate of thrombosis reported in the pivotal trials. To overcome this risk, the use of 
magnetic levitation instead of mechanical bearings has been introduced in two 
different LVAD devices (12, 13). 
 Despite such advances in technology and evidence, uncertainty persists on the 
comparative effectiveness and safety of LVAD. We thus aimed to conduct a 
systematic review and network meta-analysis of randomized trials on LVAD for HF, 
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in order to steer technologists, decision-makers, physicians and patients in this 
challenging clinical setting (14). 
 
METHODS 
Design 
 This review was registered on the PROSPERO International Prospective 
Register of Systematic Reviews 
(https://www.crd.york.ac.uk/prospero/display_record.asp?ID=CRD42017057734), 
and reported according to the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) guidelines (Table 1S) (15). All reviewing activities were 
conducted by two independent reviewers (EC, GBZ) in keeping with established 
methods (16, 17), with divergences solved after consensus. 
 
Search and selection 
 Potentially pertinent randomized controlled trials (RCT) on VAD were 
searched in PubMed using the dedicated Clinical Queries filter for clinical trials (set 
with the Therapy/Broad options) and the words “ventricular”, “assist”, and “device*”. 
Additional searches involved the Cochrane Library and clinicaltrials.gov. Searches 
were last updated on February 28, 2017, without language restrictions. We screened 
potentially relevant citations at the title/abstract level, then retrieved full-texts of 
apparently pertinent trials, and finally selected randomized controlled trials on LVAD 
in adult patients with end-stage HF. 
 
Abstraction and appraisal 
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 Baseline, procedural, and outcome data were abstracted, the latter according to 
the intention-to-treat principle whenever possible. The primary end-point was all 
cause death. Secondary end-points were bleeding, infection, and stroke. Additional 
endpoints were acute myocardial infarction, device failure, device thrombosis, drive-
line exit-site infection, hemolysis, hepatic dysfunction, neurological dysfunction, 
psychiatric event, renal dysfunction, respiratory dysfunction, right ventricular failure, 
and sepsis. Definitions recommended by INTERMACS were used whenever possible 
(4).  
The internal validity and risk of bias of included trials were appraised according to the 
Risk of Bias Assessment Tool recommended by the Cochrane Collaboration (18).  
 
Data synthesis and analysis 
 For descriptive purposes, dichotomous variables were reported as counts (%) 
and compared with the Fisher exact test, and continuous variables were reported as 
mean±standard deviation and compared with analysis of variance. For inferential 
purposes, network meta-analysis with a frequentist approach and a fixed-effect 
method was used to compare the incidence of adverse events between different 
LVAD using the netmeta R package (R Foundation for Statistical Computing, Vienna, 
Austria), and reported as incident relative risks (RR), with point estimates and 95% 
confidence intervals. Notably, a fixed effect model will yield exactly the same results 
as a random effects model if there is no closed loop in the network. Probability-scores 
(P-score) were generated to identify the best to worst treatment, taking into account 
precision and accuracy of effect (19). These are estimates of the ranking of each 
treatment versus the others, and summarize as stated above the degree of uncertainty 
in effect based on point estimates, confidence intervals and p-values. Notably, 
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statistical inconsistency and small study effects were not appraised formally given the 
star-shaped evidence network (Figure 1) (20, 21). 
 
RESULTS  
 From 2987 citations, 4 RCTs were included in the study, one comparing the 
HeartMate VE vs medical management (REMATCH), one the HeartMate II vs the 
HeartMate XVE (HeartMate II), one the HeartMate 3 vs HeartMate II 
(MOMENTUM 3), and one HeartWare vs HeartMate II (ENDURANCE), totaling 
1069 patients followed for an average of 20 (6 to 24) months (Table 1; Table 2S) (9, 
10, 12, 13). Trials were of high quality, notwithstanding the inherent limitation of the 
open design (Table 2S). 
 Comparison of study and patient characteristics for descriptive purposes is 
provided in Table 2. Specifically, patient age, serum creatinine, prevalence of 
ischemic heart disease as cause of HF, and prevalence of prior stroke decreased over 
the years, whereas body surface area, systolic blood pressure, the use of beta-blockers 
and cardiac resynchronization therapy increased (all p<0.05). Trends for cardiac 
index, diabetes, INTERMACS profile, use of IV inotropic drugs, diuretics, and 
angiotensinogen-converting enzyme inhibitors were not self-evident, despite 
significant differences between trials. In particular, the INTERMACS profile1-3 
describes advanced HF patients dependent on inotropic support, while INTERMACS 
profile 4-7 describe ambulatory advanced heart failure patients. The difference 
observed among the trials are in favor of more critically advanced HF patients, with 
progressive organ dysfunction despite inotropic support, enrolled in the studies, which 
should be taken into account when comparing the adverse events rate. 
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 Incident rate reported as event/100 patients followed for 1 year and incident 
rate ratios are provided in detail in Table 3. 
Inferential analysis for death, using HeartMate XVE/VE as benchmark, showed that 
the RR for death was 0.71 (95% confidence interval=0.44-1.14; P-score=0.914) for 
HeartMate 3, 0.80 (0.55-1.17; 0.748) for HeartMate II, 0.98 (0.61-1.56; 0.404) for 
HeartWare, and 1.47 (1.19-2.03; 0.016) for medical management (Figure 2; Tables 
3S-4S).  
 Appraising other outcomes (Tables 5S-33S; Figures 2S-16S), new-generation 
devices (HeartMate 3 and/or HeartWare) proved better than earlier devices 
(HeartMate II and HeartMate XVE/VE) for bleeding requiring surgical management 
(P-score=0.62 for HeartMate 3 and 0.43 for HeartWare), device thrombosis (P-
score=0.84 for HeartMate 3 and 0.37 for HeartWare), hemolysis (P-score=0.66 for 
HeartMate 3), hepatic dysfunction ((P-score=0.67 for HeartWare), and stroke (P-
score=0.70 for HeartMate 3).  
Instead, new-generation devices proved worse adverse events than the earlier 
continuous-flow device, the HeartMate II, for acute myocardial infarction (P-
score=0.92 for HeartMate II in comparison of 0.44 for HeartWare), device failure (P-
score=0.76 for HeartMate II in comparison to 0.41 for HeartWare), drive-line exit-site 
infection (P-score=0.72 for HeartMate II in comparison to 0.39 for HeartWare and 
0.13 for HeartMate 3), neurologic dysfunction (P-score=0.62 for HeartMate II in 
comparison to 0.54 for HeartMate 3 and 0.15 for HeartWare), psychiatric event (P-
score=0.81 for HeartMate II in comparison to 0.41 for HeartWare), renal dysfunction 
(P-score=0.91 for HeartMate II in comparison to 0.64 for HeartWare and for 
HeartMate 3), respiratory failure (P-score=0.92 for HeartMate II in comparison to 
0.59 for HeartWare and 0.49 for HeartMate 3), right ventricular failure (P-score=0.73 
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for HeartMate II in comparison to 0.46 for HeartMate 3 and 0.31 for HeartWare), and 
sepsis (P-score=0.72 for HeartMate II in comparison to 0.42 for HeartMate 3 and 0.38 
for HeartWare). Overall the continuous-flow devices showed a significant reduction 
in the adverse event in comparison with the axial-flow devices HeartMate VE/XVE.   
(Figure 3, Summarizing Figure).  
 
DISCUSSION 
 
 LVAD are technological tools originally intended to provide circulatory 
support for patients at risk of death from refractory, end-stage HF. However, LVAD 
have progressively evolved their indication, becoming a treatment to support end-
stage HF patients in several different clinical scenarios: as a bridge to heart 
transplantation, as a destination therapy, as bridge to decision or even as recovery (1). 
Following the creation of the INTERMACS registry, patient profile at the time of 
implant continues to evolve (5). With first-generation devices the majority of LVAD 
implantations were accordingly performed in patients hospitalized and dependent on 
intravenous inotropic support, whereas today the trend is becoming the anticipated 
implantation in ambulatory advanced HF patient with the aim of an improvement in 
survival and maximization of life quality (22, 23). Despite that, the most recent 
randomized trials have been performed with more critically HF patients, as 
demonstrated by the increased number of patients in INTERMACS profile 1-3. Since 
the natural commitment of LVAD is eventual heart transplantation, lifetime support 
or a bridge to recovery, research efforts of the last years have been focused mainly on 
improving overall device safety, durability and performance (24, 25). However, since 
these treatment strategies are complex, multifaceted and not devoid of several adverse 
effects that impose a significant burden on patients and public health, and there are no 
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conclusive trials comparing different devices, we aimed at summarizing the evidence 
base on LVAD for adult patients with end-stage HF. 
 The main findings of the present meta-analysis including 4 RCTs and 1069 
patients are: [1] overall, mortality is significantly reduced with all LVAD as 
compared with medical management, in particular with the new-generation LVAD; 
[2] despite advances in technology, continuous-flow pumps maintain a high risk of 
adverse events, but significantly less than first-generation pulsatile-flow devices; [3] 
the risk of many clinically relevant adverse events, such as drive-line exit-site 
infection, hepatic dysfunction, neurological dysfunction, renal dysfunction, right 
ventricular dysfunction, stroke and sepsis, is markedly reduced with centrifugal 
continuous-flow pumps as compared with first-generation pulsatile-flow pumps. 
 It is established that survival after LVAD implant has improved significantly 
(9, 10, 12, 13, 26-29), and with newer generation devices outcomes might continue to 
improve. One of the key benefits of LVAD implantation, over the hemodynamic 
support, is the ability to unload the left ventricle and reverse pathologic remodeling. 
This may allow for recovery of myocardial function and for a reduction of pulmonary 
vascular resistance in preparation for transplantation (30-33). Of note, advantages of 
continuous-flow pumps over pulsatile first-generation LVAD, include miniaturized 
size, increased mechanical durability and hemodynamic efficiency, and improved 
bridge to transplant rates (1). Optimization of the medical management and a better 
understanding of the risk factors for early mortality after LVAD implantation as 
advanced age, female gender, obesity, INTERMACS profile 1-2, previous stroke, 
renal dysfunction, previous or concomitant need for cardiac surgery and receiving 
LVAD support in a less experienced center (4, 34) will help in patient selection 
process and further increase survival after LVAD implant.  
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 Performing a RCT of LVAD is complex and expensive, and no RCT have 
been conducted on LVAD approved solely in Europe, despite the availability of 
observational studies and registries on these devices (35). Indeed, a higher degree of 
freedom to implant devices exists in Europe, as resulted by the first report of the 
EUROMACS registry (29), despite the weaker evidence based. Indeed, this meta-
analysis is the first work that could help in the complex decision to implant a specific 
LVAD, but further larger studies are needed to compare different LVADs. Although 
most RCTs have measured nominally identical safety and effectiveness endpoints, no 
consensus criteria on endpoint definitions exist that could provide consistency across 
studies and further facilitate the comparative evaluation of these devices, as it happens 
for coronary stents (36) and transcatheter aortic valve implantation (37).  
 Moreover, the present meta-analysis raise a crucial question: how come that, 
despite the technological advances, newer LVAD have not yet resolved the high rate 
of adverse events, which remains one of the most important issues with LVAD 
support as destination therapy (38)? The first important issue with continuous flow 
pumps is the method used to suspend the rotor. Early versions (HeartMate II) used 
solid bearings, meanwhile newer pumps, some of which are approved for use in the 
EU, use either magnetic levitation ("maglev") or hydrodynamic suspension 
(HeartMate III, HeartWare). In theory this operating mode implies that magnetically 
levitated pump rotor does not make any contact with any other part of the system and 
accordingly should prevents damage to passing blood cells also reducing the chance 
of a clot formation due to the pumping mechanism. Moreover, in newer pumps, 
physiologic control algorithms are incorporated for safe operation. The HeartMate III, 
for example, actually matches its pumping action to the natural heartbeat of the 
patient. This makes the blood flow more natural and should also help avoid clot 
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formation by pump washing. Once again, since there is no friction in magnetically 
levitated pump and therefore less wear and tear on the rotor, consequently technical 
failure of these pumps should be reduced in comparison to first generation device. 
Up-to-date only short-term (6 months) results from the Momentum 3 trial have been 
published (12), but long-term data from a larger cohort of all-comer HF patients will 
be pivotal to demonstrate the superiority of HeartMate 3 over HeartMate II (39).  
Despite the above-mentioned technical issues, it is noteworthy that the introduction of 
new-generation LVADs have not markedly reduced the adverse events rate, in 
particular sepsis, right ventricular dysfunction and drive-line exit-site infection. We 
might speculate that the study populations are markedly different, as demonstrated by 
the significant changes in the INTERMACS profile, therefore we must critically read 
the results. In terms of resource use, on top of differences in device cost, adverse 
events are one of the other major drivers of implantation and follow-up costs (40), 
therefore the high rate of adverse events even with the newer generation LVADs still 
represents a missed opportunity. Last but not least, in the absence of larger trials 
comparing different devices, being aware of which adverse event is the most probable 
one with the use of a specific LVAD may help surgeons and HF team specialists in 
choosing the most appropriate LVAD for a specific patient. 
 This work has all the limitations typical of network meta-analyses based on a 
star-shaped evidence network. Moreover, small study effect and inconsistency 
appraisal were beyond our scope. An important underlying assumption was also 
lumping together HeartMate VE and HeartMate XVE in the same treatment group. 
Though, this is amply justified by the minor modifications made to the HeartMate VE 
leading to the HeartMate XVE, such as redesigned percutaneous lead (41). Finally, P-
scores provide a probability ranking but cannot be equated to statistical significance 
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tests, and simply provide a summary of the uncertainty/certainty in treatment ranking 
based on point estimates and confidence intervals of effect, even if the single point 
estimate and confidence interval appear not significant. 
 In conclusion, new-generation LVAD represent a paradigm shift in the 
management of end-stage HF with a significant reduction in mortality in comparison 
with medical therapy for newer generation LVAD. Further technological refinements, 
higher quality and larger trials are crucial to improve decision-making and clinical 
outcomes in this challenging clinical setting. 
 
Sources of funding: this study was partially funded by Sapienza University of Rome 
(grant number 43780/2016) to Elena Cavarretta.  
  14 
REFERENCES 
1. Gustafsson F, Rogers JG. Left ventricular assist device therapy in advanced heart 
failure: patient selection and outcomes. Eur J Heart Fail. 2017;19(5):595-602. doi: 
10.1002/ejhf.779.  
2. Wever-Pinzon O, Drakos SG, McKellar SH, Horne BD, Caine WT, Kfoury AG, Li 
DY, Fang JC, Stehlik J, Selzman CH. Cardiac Recovery During Long-Term Left 
Ventricular Assist Device Support. J Am Coll Cardiol. 2016;68(14):1540-53. doi: 
10.1016/j.jacc.2016.07.743. 
3. Frazier OH, Baldwin AC, Demirozu ZT, Segura AM, Hernandez R, Taegtmeyer H, 
Mallidi H, Cohn WE. Ventricular reconditioning and pump explantation in patients 
supported by continuous-flow left ventricular assist devices. J Heart Lung 
Transplant. 2015;34(6):766-72. doi: 10.1016/j.healun.2014.09.015. 
4. Kirklin JK, Naftel DC, Pagani FD, Kormos RL, Stevenson LW, Blume ED, Myers 
SL, Miller MA, Baldwin JT, Young JB. Seventh INTERMACS annual report: 
15,000 patients and counting. J Heart Lung Transplant. 2015;34(12):1495-504. 
5. Cowger J, Shah P, Stulak J, Maltais S, Aaronson KD, Kirklin JK, Pagani FD, 
Salerno C. INTERMACS profiles and modifiers: Heterogeneity of patient 
classification and the impact of modifiers on predicting patient outcome. J Heart 
Lung Transplant. 2016;35(4):440-8. doi:10.1016/j.healun.2015.10.003. 
6. Kirklin JK. Terminal heart failure: who should be transplanted and who should 
have mechanical circulatory support? Curr Opin Organ Transplant. 2014;19(5):486-
93. doi: 10.1097/MOT.0000000000000120. 
7. De Castro S, Salandin V, Cavarretta E, Salvador L, Valfré C, Caselli S, Di 
  15 
Michele S, Faletra F, Pandian NG. Epicardial real-time three-dimensional 
echocardiography in cardiac surgery: a preliminary experience. Ann Thorac Surg. 
2006;82(6):2254-9. 
8. Hetzer R, Kaufmann MEng F, Potapov E, Krabatsch T, Delmo Walter EM. Rotary 
Blood Pumps as Long-Term Mechanical Circulatory Support: A Review of a 15-
Year Berlin Experience. Semin Thorac Cardiovasc Surg. 2016;28(1):12-23. doi: 
10.1053/j.semtcvs.2016.01.001. 
9. Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsky W, 
Long JW, Ascheim DD, Tierney AR, Levitan RG, Watson JT, Meier P, Ronan NS, 
Shapiro PA, Lazar RM, Miller LW, Gupta L, Frazier OH, Desvigne-Nickens P, Oz 
MC, Poirier VL; Randomized Evaluation of Mechanical Assistance for the 
Treatment of Congestive Heart Failure (REMATCH) Study Group.. Randomized 
Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure 
(REMATCH) Study Group. Long term use of a left ventricular assist device for end-
stage heart failure. N Engl J Med 2001;345:1435-43. 
10. Slaughter MS, Rogers JG, Milano CA, Russell SD, Conte JV, Feldman D, Sun B, 
Tatooles AJ, Delgado RM 3rd, Long JW, Wozniak TC, Ghumman W, Farrar DJ, 
Frazier OH; HeartMate II Investigators.. HeartMate II Investigators. Advanced heart 
failure treated with continuous-flow left ventricular assist device. N Engl J Med 
2009;361:2241-51. doi: 10.1056/NEJMoa0909938. 
11. Starling RC, Moazami N, Silvestry SC, Ewald G, Rogers JG, Milano CA, Rame 
JE, Acker MA, Blackstone EH, Ehrlinger J, Thuita L, Mountis MM, Soltesz EG, 
Lytle BW, Smedira NG. Unexpected abrupt increase in left ventricular assist device 
thrombosis. N Engl J Med. 2014;370(1):33-40. doi: 10.1056/NEJMoa1313385. 
12. Mehra MR, Naka Y, Uriel N, Goldstein DJ, Cleveland JC Jr, Colombo PC, Walsh 
  16 
MN, Milano CA, Patel CB, Jorde UP, Pagani FD, Aaronson KD, Dean DA, McCants 
K, Itoh A, Ewald GA, Horstmanshof D, Long JW, Salerno C; MOMENTUM 3 
Investigators.. A Fully Magnetically Levitated Circulatory Pump for Advanced 
Heart Failure. N Engl J Med 2017;376:440-450. doi: 10.1056/NEJMoa1610426. 
13. Rogers JG, Pagani FD, Tatooles AJ, Bhat G, Slaughter MS, Birks EJ, Boyce SW, 
Najjar SS, Jeevanandam V, Anderson AS, Gregoric ID, Mallidi H, Leadley K, 
Aaronson KD, Frazier OH, Milano CA. Intrapericardial Left Ventricular Assist 
Device for Advanced Heart Failure. N Engl J Med 2017;376:451-460. doi:  
10.1056/NEJMoa1602954. 
14. Biondi-Zoccai G, Abbate A, Benedetto U, Palmerini T, D'Ascenzo F, Frati G. 
Network meta-analysis for evidence synthesis: what is it and why is it posed to 
dominate cardiovascular decision making? Int J Cardiol. 2015;182:309-14. doi: 
10.1016/j.ijcard.2015.01.023. 
15. Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, 
Ioannidis JP, Straus S, Thorlund K, Jansen JP, Mulrow C, Catalá-López F, Gøtzsche 
PC, Dickersin K, Boutron I, Altman DG, Moher D. The PRISMA extension 
statement for reporting of systematic reviews incorporating network meta-analyses 
of health care interventions: checklist and explanations. Ann Intern Med 
2015;162::777-84. doi: 10.7326/M14-2385. 
16. Biondi-Zoccai G, editor. Network Meta-Analysis: Evidence Synthesis with Mixed 
Treatment Comparison. Hauppauge, NY: Nova Science Publishers, 2014. 
17. Biondi-Zoccai G, editor. Umbrella Reviews: Evidence Synthesis with Overviews 
of Reviews and Meta-Epidemiologic Studies. Cham: Springer International 
Publishing, 2016. 
  17 
18. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of 
Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 
2011. Available at: http://handbook.cochrane.org. Accessed February 28, 2017. 
19. Rücker G, Schwarzer G. Automated drawing of network plots in network meta-
analysis. Res Synth Methods 2016;7:94-107. 
20. Biondi-Zoccai GG, Agostoni P, Abbate A, Testa L, Burzotta F, Lotrionte M, Crea 
F, Biasucci LM, Vetrovec GW, Colombo A. Adjusted indirect comparison of 
intracoronary drug-eluting stents: evidence from a metaanalysis of randomized bare-
metal-stent-controlled trials. Int J Cardiol 2005;100:119-23. 
21. Biondi-Zoccai G, Lotrionte M, Agostoni P, Abbate A, Romagnoli E, Sangiorgi G,  
Angiolillo DJ, Valgimigli M, Testa L, Gaita F, Sheiban I. Adjusted indirect 
comparison meta-analysis of prasugrel versus ticagrelor for patients with acute 
coronary syndromes. Int J Cardiol 2011;150:325-31. doi: 
10.1016/j.ijcard.2010.08.035. 
22. Netuka I, Sood P, Pya Y, Zimpfer D, Krabatsch T, Garbade J, Rao V, Morshuis 
M, Marasco S, Beyersdorf F, Damme L, Schmitto JD. Fully Magnetically Levitated 
Left Ventricular Assist System for Treating Advanced HF: A Multicenter Study. J 
Am Coll Cardiol. 2015;66(23):2579-89. doi: 10.1016/j.jacc.2015.09.083.23.  
23. Nunes AJ, MacArthur RG, Kim D, Singh G, Buchholz H, Chatterley P, 
Klarenbach SW. A Systematic Review of the Cost-Effectiveness of Long-Term 
Mechanical Circulatory Support. Value Health. 2016 Jun;19(4):494-504. doi: 
10.1016/j.jval.2014.12.020. 
24. Silva Enciso J. Mechanical Circulatory Support: Current Status and Future 
Directions. Prog Cardiovasc Dis. 2016;58(4):444-54. doi: 
10.1016/j.pcad.2016.01.006. 
  18 
25. Health Quality Ontario.. Left Ventricular Assist Devices for Destination Therapy: 
A Health Technology Assessment. Ont Health Technol Assess Ser. 2016;16(3):1-60. 
eCollection 2016. 
26. Estep JD, Starling RC, Horstmanshof DA, Milano CA, Selzman CH, Shah KB, 
Loebe M, Moazami N, Long JW, Stehlik J, Kasirajan V, Haas DC, O'Connell JB, 
Boyle AJ, Farrar DJ, Rogers JG; ROADMAP Study Investigators.. Risk Assessment 
and Comparative Effectiveness of Left Ventricular Assist Device and Medical 
Management in Ambulatory Heart Failure Patients: Results From the ROADMAP 
Study. J Am Coll Cardiol. 2015;66(16):1747-61. doi: 10.1016/j.jacc.2015.07.075. 
27. Aaronson KD, Slaughter MS, Miller LW, McGee EC, Cotts WG, Acker MA, 
Jessup ML, Gregoric ID, Loyalka P, Frazier OH, Jeevanandam V, Anderson AS, 
Kormos RL, Teuteberg JJ, Levy WC, Naftel DC, Bittman RM, Pagani FD, 
Hathaway DR, Boyce SW; HeartWare Ventricular Assist Device (HVAD) Bridge to 
Transplant ADVANCE Trial Investigators.. Use of an intrapericardial, continuous-
flow, centrifugal pump in patients awaiting heart transplantation. Circulation. 
2012;125(25):3191-200. doi: 10.1161/CIRCULATIONAHA.111.058412. 
28. Boyle AJ, Ascheim DD, Russo MJ, Kormos RL, John R, Naka Y, Gelijns AC, 
Hong KN, Teuteberg JJ. Clinical outcomes for continuous-flow left ventricular 
assist device patients stratified by pre-operative INTERMACS classification. J Heart 
Lung Transplant. 2011;30(4):402-7. doi: 10.1016/j.healun.2010.10.016. 
29. de By TM, Mohacsi P, Gummert J, Bushnaq H, Krabatsch T, Gustafsson F, 
Leprince P, Martinelli L, Meyns B, Morshuis M, Netuka I, Potapov E, Zittermann 
A, Delmo Walter EM, Hetzer R; EUROMACS members.. The European Registry 
for Patients with Mechanical Circulatory Support (EUROMACS): first annual 
report. Eur J Cardiothorac Surg. 2015;47(5):770-6; discussion 776-7. doi: 
  19 
10.1093/ejcts/ezv096.  
30. Drakos SG, Wever-Pinzon O, Selzman CH, Gilbert EM, Alharethi R, Reid BB, 
Saidi A, Diakos NA, Stoker S, Davis ES, Movsesian M, Li DY, Stehlik J, Kfoury 
AG; UCAR (Utah Cardiac Recovery Program) Investigators.. Magnitude and time 
course of changes induced by continuous-flow left ventricular assist device 
unloading in chronic heart failure: insights into cardiac recovery. J Am Coll Cardiol. 
2013;61(19):1985-94. doi: 10.1016/j.jacc.2013.01.072. 
31. Wever-Pinzon J, Selzman CH, Stoddard G, Wever-Pinzon O, Catino A, Kfoury 
AG, Diakos NA, Reid BB, McKellar S, Bonios M, Koliopoulou A, Budge D, 
Kelkhoff A, Stehlik J, Fang JC, Drakos SG. Impact of Ischemic Heart Failure 
Etiology on Cardiac Recovery During Mechanical Unloading. J Am Coll Cardiol. 
2016;68(16):1741-1752. doi: 10.1016/j.jacc.2016.07.756. 
32. Chimenti I, Pagano F, Cavarretta E, Angelini F, Peruzzi M, Barretta A, Greco 
E, De Falco E, Marullo AG, Sciarretta S, Biondi-Zoccai G, Frati G. Β-blockers 
treatment of cardiac surgery patients enhances isolation and improves phenotype of 
cardiosphere-derived cells. Sci Rep. 2016;6:36774. doi:10.1038/srep36774. 
33. Cavarretta E, Condorelli G. miR-21 and cardiac fibrosis: another brick in the 
wall? Eur Heart J. 2015;36(32):2139-41. doi: 10.1093/eurheartj/ehv184. 
34. Cowger J, Sundareswaran K, Rogers JG, Park SJ, Pagani FD, Bhat G, Jaski B, 
Farrar DJ, Slaughter MS. Predicting survival in patients receiving continuous flow left 
ventricular assist devices: the HeartMate II risk score. J Am Coll Cardiol. 
2013;61(3):313-21. doi: 10.1016/j.jacc.2012.09.055. 
35. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, 
González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, 
Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, 
  20 
Ruschitzka F, Rutten FH, van der Meer P; Authors/Task Force Members.. 2016 ESC 
Guidelines for the diagnosis and treatment of acute and chronic heart failure: The 
Task Force for the diagnosis and treatment of acute and chronic heart failure of the 
European Society of Cardiology (ESC) Developed with the special contribution of 
the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129-
200. doi: 10.1093/eurheartj/ehw128. 
36. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, 
Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, 
Serruys PW; Academic Research Consortium.. Clinical end points in coronary stent 
trials: a case for standardized definitions. Circulation. 2007;115(17):2344-51. 
37. Kappetein AP, Head SJ, Généreux P, Piazza N, van Mieghem NM, Blackstone 
EH, Brott TG, Cohen DJ, Cutlip DE, van Es GA, Hahn RT, Kirtane AJ, Krucoff 
MW, Kodali S, Mack MJ, Mehran R, Rodés-Cabau J, Vranckx P, Webb JG, 
Windecker S, Serruys PW, Leon MB. Updated standardized endpoint definitions for 
transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 
consensus document. J Am Coll Cardiol. 2012;60(15):1438-54. doi: 
10.1016/j.jacc.2012.09.001. 
38. Hetzer R, Delmo Walter EM. Mechanical Circulatory Support Devices - In 
Progress. N Engl J Med. 2017;376(5):487-489. doi: 10.1056/NEJMe1613755. 
39. Pinney SP, Anyanwu AC, Lala A, Teuteberg JJ, Uriel N, Mehra MR. Left 
Ventricular Assist Devices for Lifelong Support. J Am Coll Cardiol. 
2017;69(23):2845-2861. doi: 10.1016/j.jacc.2017.04.031. 
40. Oz MC, Gelijns AC, Miller L, Wang C, Nickens P, Arons R, Aaronson K, 
  21 
Richenbacher W, van Meter C, Nelson K, Weinberg A, Watson J, Rose EA, 
Moskowitz AJ. Left ventricular assist devices as permanent heart failure therapy: the 
price of progress. Ann Surg. 2003;238(4):577-83. 
41. Dowling RD, Park SJ, Pagani FD, Tector AJ, Naka Y, Icenogle TB, Poirier VL, 
Frazier OH. HeartMate VE LVAS design enhancements and its impact on device 
reliability. Eur J Cardiothorac Surg. 2004;25(6):958-63. 
 
 
 
Figure Legend 
 
Figure 1. Evidence network geometry. 
 
Figure 2. Forest plot for death. CI=confidence interval. RR=relative risk. 
 
Figure 3. Summarizing Figure. Synthesis on the comparative effectiveness of left 
ventricular assist devices in patients with end-stage heart failure, focusing on death 
and several other key clinical outcomes, identifying the best to worst treatments. 
 
